Abstract: 7-Substituted imidazo[2,1-b]thiazolium and 9-substitutedthiazolo[3,2-a]benzimidazolium salts as blood-sugar lowering agents and growth promotants.

Abstract: The synthesis of imidazo[1,2-a]pyridinium, imidazo[1,5-a]pyridinium, pyrrolo[1,2-a]pyrazinium, pyrazolo[1,5-a]pyridinium, imidazo[2,1-a]isoquinolinium and imidazo[5,1-a]isoquinolinium quaternary salts and their use as hypoglycemic agents.

Abstract: 7-Substituted imidazo[2,1-b]thiazolium and 9-substitutedthiazolo[3,2-a]benzimidazolium salts as blood-sugar lowering agents and growth promotants.

Abstract: 7-Substituted imidazo[2,1-b]thiazolium and 9-substituted thiazolo-[3,2-a]benzimidazolium salts as blood-sugar lowering agents and growth promotants.

Abstract: The novel process for the preparation of methyl 3-(2-quinoxalinylmethylene)carbazate N.sup.1, N.sup.4 -dioxide which comprises contacting methyl 3-(2-quinoxalinylmethylene)carbazate with oxidizing agent in reaction-inert solvent at a temperature of from about 20.degree. up to 100.degree. C. until reaction is substantially complete, said oxidizing agent being selected from the group consisting of peracetic acid, perbenzoic acid, m-chloroperbenzoic acid, perphthalic acid, performic acid, trifluoroperacetic acid and hydrogen peroxide.

Abstract: 6-AMINO AND 6-(N-protected amino)-2,2-dimethyl-3-cyanopenams, intermediates therefor, and a process for the conversion of the 3-cyano penams, by reaction with a source of azide ion in a reaction inert solvent, to 6-amino- and 6-(N-protected amino)-2,2-dimethyl-3(5-tetrazolyl)penams, intermediates for the preparation of antibacterial agents.

Abstract: Disclosed herein is an improved process for the preparation of known hypoglycemic piperidinesulfamylureas of the structue ##SPC1##Wherein R is selected from the group consisting of 3-(2-methoxy)pyridyl, 3-(2-ethoxy)pyridyl and 2-(4-chloro)pyridyl and R' is selected from the group consisting of bicyclo[2.2.1]hept-5-en-2-yl-endo-methyl, bicyclo[2.2.1]hept-2-yl-endo-methyl, 7-oxabicyclo[2.2.1]hept-2-yl-methyl, 1-adamantyl and cycloalkyl having from five to eight carbon atoms.Said process comprises contacting 4-(2-pyridyl-amidoethyl) piperidine of the structue ##SPC2##With substantially one equivalent of sulfamide thereby exclusively sulfonating the piperidine nitrogen atom.

Abstract: A series of novel 1-piperidinesulfonylurea compounds derived from a nitrogen-containing monocarboxylic acid have been prepared by reacting an appropriate sulfamide with an organic isocyanate or a trisubstituted urea equivalent thereof. The sulfamylureas so obtained are useful in therapy as oral hypoglycemic agents. Typical members include those compounds derived from 2-methoxynicotinic acid, of which 1-(bicyclo[2.2.1]hept-5-en-2-yl-endo-methyl)-3-{4-[2-(2-methoxynicotinamid o)ethyl]-1-piperidinesulfonyl}-urea is a most preferred embodiment.

Abstract: Certain novel benzenesulfonylurea compounds derived from a nitrogen-containing carboxylic acid have been prepared by reacting an appropriate sulfonamide with an organic isocyanate or a tri-substituted urea equivalent thereof. The sulfonylureas so obtained are useful in therapy as oral hypoglycemic agents. Typical members include those compounds derived from 2-methoxy-nicotinic acid, of which 1-cyclohexyl-3-{4-[2-(5-bromo-2-methoxynicotinamido)ethyl]benzenesulfonyl} urea is a most preferred embodiment.

Abstract: Several benzenesulfonylurea compounds derived from 4-methyl-5-thiazolecarboxylic acid have been prepared by reacting 4-[2-(4-methyl-5-thiazolecarboxamido)ethyl]benzenesulfonamide with an appropriate organic isocyanate or a trisubstituted urea equivalent thereof. The sulfonylureas so obtained are useful in therapy as oral hypoglycemic agents. 1-Cyclohexyl-3-{4-[2-(4-methyl-5-thiazolecarboxamido)ethyl]benzenesulfonyl }urea represents a preferred embodiment.

Abstract: 7-Substituted imidazo[2,1-b]thiazolium and 9-substitutedthiazolo-[3,2-a]benzimidazolium salts as blood-sugar lowering agents and growth promotants.

Abstract: A series of novel 1-piperidinesulfonylurea compounds derived from a nitrogen-containing monocarboxylic acid have been prepared by reacting an appropriate sulfamide with an organic isocyanate or a trisubstituted urea equivalent thereof. The sulfamylureas so obtained are useful in therapy as oral hypoglycemic agents. Typical members include those compounds derived from 2-methoxynicotinic acid, of which 1-(bicyclo[2.2.1]hept-5-en-2-yl-endomethyl)-3-{4-[2-(2-methoxynicotinamido )ethyl]-1-piperidinesulfonyl}urea is a most preferred embodiment.

Abstract: Disclosed herein is an improved process for the preparation of known hypoglycemic piperidinesulfamylureas of the structure ##EQU1## wherein R is selected from the group consisting of 3-(2-methoxy)pyridyl, 3-(2-ethoxy)pyridyl and 2-(4-chloro)pyridyl and R' is selected from the group consisting of bicyclo[2.2.1]hept-5-en-2-yl-endo-methyl, bicyclo[2.2.1]hept-2-yl-endo-methyl, 7-oxabicyclo[2.2.1]hept-2-yl-methyl, 1-adamantyl and cycloalkyl having from five to eight carbon atoms.Said process comprises contacting 4-(2-pyridyl-amidoethyl) piperidine of the structure ##EQU2## with substantially one equivalent of sulfamide thereby exclusively sulfonating the piperidine nitrogen atom.